Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 294 participants.
Also called NCT01940965
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 294 participants
- Sponsor
- Registry
-
NCT01940965
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01940965. Non-randomized; no masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2015-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- lixisenatide AVE0010
- Intervention (Drug)
- biguanide
- Intervention (Drug)
- TZD
- Intervention (Drug)
- alpha-GI
- Intervention (Drug)
- glinide
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01940965- Content hash
44d7677079908946f34cb3048c59d909305bc6a9f2ee7ef556fef03476af2d16